Silence is deafening when new drugs are not approved

You are here: Home > Columns > Current Article

Silence is deafening when new drugs are not approved

By Philip Joens / Friday, August 5th, 2016 / Comments Off on Silence is deafening when new drugs are not approved

Philip Joens When word leaked that the Food and Drug Administration declined to approve a Novartis biosimilar of an Amgen drug July 19, there was silence from the pharmaceuticals. But when regulators like the FDA or the European Medicines Agency approve new drugs, the news is celebrated by companies as if fireworks should explode and…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.